SUMMARY
Siddhartha Yadav, M.B.B.S., M.D., is a clinical and translational researcher. His primary focus is the identification of genes and genetic variants associated with susceptibility to breast and gynecological malignancies.
Dr. Yadav's research includes the molecular biology and clinical outcomes of breast and gynecological cancers in individuals harboring germline pathogenic variants in DNA repair genes. Germline refers to the cells in the egg and sperm that combine in conception. These cells are present in individuals from birth.
Dr. Yadav leads studies aimed at elucidating key molecular pathways driving therapeutic resistance in breast and ovarian cancers. These pathways facilitate the identification of precision-guided therapeutic targets and the development of individualized treatment strategies.
Dr. Yadav's research is generously supported by several organizations, including the Mayo Clinic Breast Cancer Specialized Program of Research Excellence, Mayo Clinic Ovarian Cancer Specialized Program of Research Excellence, Conquer Cancer Foundation of the American Society of Clinical Oncology, and the Breast Cancer Research Foundation.
Focus areas
Understanding genetic predisposition to breast or ovarian cancer. Dr. Yadav's research is dedicated to unraveling the genetic predisposition to breast and ovarian cancers. Employing rigorous genetic epidemiology and functional studies, he has successfully identified genes and genetic variants intricately involved in the susceptibility to these cancers.
Dr. Yadav's work contributes to the refinement of personalized risk assessment for breast cancer among people with germline pathogenic variants in cancer predisposition genes. He also studies pertinent clinical factors such as age, race, ethnicity and family history. The insights derived from his studies play a pivotal role in shaping national guidelines pertaining to germline genetic testing, breast cancer risk assessment and the development of effective cancer prevention strategies.
Characterization of the tumor biology and clinical outcomes of breast or ovarian cancer in people who carry germline variants. Dr. Yadav leads investigations into the characterization of tumor biology of breast and ovarian cancers associated with DNA damage repair deficiencies.
His research initiatives involve a comprehensive examination of markers indicative of chemotherapy and endocrine sensitivity. Dr. Yadav studies the molecular pathways contributing to the progression of breast cancer among individuals carrying germline pathogenic variants in cancer predisposition genes. These genes include ATM, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D and others.
Dr. Yadav researches the systematic assessment of clinical outcomes among people who carry germline variants for breast or ovarian cancer. The insights derived from these investigations are instrumental for evidence-based management strategies tailored to the unique needs of this specific population.
Precision genomics and early-phase clinical trials. In his pursuit of precision medicine, Dr. Yadav identifies critical genetic alterations within breast and gynecological cancers in order to guide the development of novel, precision-guided therapeutic interventions. These interventions are highly tailored to an individual's tumor profile.
At Mayo Clinic, Dr. Yadav leads multiple precision-guided clinical trials. These trials encompass a wide range of strategies, including interventions targeting DNA repair pathways and reversing resistance mechanisms associated with PARP and CDK4/6 inhibitors. He researches innovative approaches involving the manipulation of the immune microenvironment through the intratumoral administration of a novel oncolytic virus.
Significance to patient care
Dr. Yadav's commitment to bridging the gap between innovative scientific discoveries and clinical applications stands as a defining characteristic of his research endeavors. His work is aimed at enhancing the precision and efficacy of cancer treatment, with the ultimate goal of improving outcomes.
His research contributions have been instrumental in advancing the field of personalized cancer management and prevention, particularly in cases involving germline variations in cancer predisposition genes. Dr. Yadav's investigation extends to elucidating key genetic alterations inherent in a person's cancer. This facilitates the identification of relevant clinical trial opportunities.
His research approach enables the strategic application of novel targeted therapies and immunotherapy. This strategy benefits people and ultimately expands the landscape of therapeutic options available for individuals with breast or ovarian cancer.
Professional highlights
- Member, Cancer Treatment During Pregnancy Guideline Panel, American Society of Clinical Oncology, 2023-present.
- Member, Health Equity and Outcomes Committee, American Society of Clinical Oncology, 2023-present.
- Member, Germline Testing in Breast Cancer Guideline Panel, American Society of Clinical Oncology, The Society of Surgical Oncology, 2022-present.
- Career Development Award, American Society of Clinical Oncology, 2023.
- Developmental Research Program Award, Mayo Clinic Ovarian Cancer Specialized Program of Research Excellence, Mayo Clinic, 2021, 2023.
- Marion Wright Award for Scientific Excellence, Breast Cancer Research Foundation, 2023.
- Career Enhancement Program Award, Mayo Clinic Breast Cancer Specialized Program of Research Excellence, Mayo Clinic, 2022.
- National Research Grant, Halt Cancer at X, 2022.
- Women's Cancer Program Pilot Project Award, Mayo Clinic, 2022.
- Paul Calabresi Award in Clinical-Translation Research, Mayo Clinic, 2021.
- Breast Cancer Specialized Program of Research Excellence Developmental Research Project Award, Mayo Clinic, 2020.
- Mayo Brothers Distinguished Fellowship Award, Mayo Clinic, 2020.
- William H. J. Summerskill Award, Mayo Clinic, 2020.
- Young Investigator Award, American Society of Clinical Oncology, 2019.